Discovery Dialogues at Insmed
Sit down with members of Insmed’s global Research team as they discuss our approach to developing life-transforming medicines while tackling some of the most pressing scientific challenges today.
Platforms & Technologies
Targeted Gene Therapy
Learn how we are pioneering the development of next-generation gene therapies to potentially address many of the current challenges in this space.
Protein Deimmunization
Discover how our proprietary Deimmunized by Design® platform offers a potential solution to addressing immunogenicity challenges presented by both gene therapies and protein therapeutics.
RNA End-Joining
Hear how our proprietary RNA end-joining technology may enable us to treat diseases caused by genes previously considered too large to address with gene therapy.
Synthetic Rescue
Find out how our leading synthetic rescue platform couples cutting-edge molecular and cell biology techniques with sophisticated analysis of human genetics datasets to potentially treat a broad range of diseases.
Proprietary Manufacturing
Learn how we aim to address the cost and complexity of current cell production approaches by harnessing the unique properties of algae.
Our Research Team
Synergies Among the Research Team
From New Jersey to San Diego, New Hampshire to Cambridge, UK, find out how our global Research team collaborates to deliver meaningful results for patients.
Disease Areas
Amyotrophic Lateral Sclerosis (ALS)
Our team discusses our work in ALS, a progressive and fatal neurological disorder affecting the nerve cells in the brain and spinal cord that control voluntary muscle movement and breathing.
Argininosuccinic Aciduria (ASA)
Hear our team discuss our approach to potentially tackling ASA, a rare genetic disorder that causes ammonia to accumulate in the blood.
Ataxia Telangiectasia (AT)
Learn about our work in AT, an inherited, fatal childhood disorder driven by mutations in a gene involved in DNA damage repair.
Chronic Refractory Gout
Watch as our team discusses our research into this rare form of gout, which is caused by the buildup of uric acid in the body.
Duchenne Muscular Dystrophy (DMD)
Learn about our work in DMD, a rare genetic disorder that causes progressive muscle weakness and degeneration.
Stargardt Disease
Hear our team discuss how we plan to help tackle Stargardt disease, a rare genetic eye disease that leads to the loss of central vision in both eyes.
These videos may contain forward-looking statements that involve substantial risks and uncertainties. “Forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. Words such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “intends,” “potential,” “continues,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) may identify forward-looking statements.
Any forward-looking statements included are based upon the Company’s current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause the Company’s actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timings discussed, projected, anticipated or indicated in any forward-looking statements.
The Company may not actually achieve the results, plans, intentions or expectations indicated by the Company’s forward-looking statements because, by their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. For additional information about the risks and uncertainties that may affect the Company’s business, please see the factors discussed in Item 1A, “Risk Factors,” in the Company’s most recently filed Annual Report on Form 10-K and any subsequent Company filings with the Securities and Exchange Commission (SEC).
The Company cautions viewers not to place undue reliance on any such forward-looking statements, which speak only as of the date the videos were recorded. The Company disclaims any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
Your Privacy Choices
